Lundbeck and Otsuka announce decision to continue phase III clinical trial evaluating brexpiprazole for treatment of agitation in patients with Alzheimer’s-type dementia
Valby, Denmark and Tokyo, Japan, 13 April 2021 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type (NCT03548584). The decision to continue the trial is based on the results of an independent interim analysis, supporting to progress the trial to the planned full enrollment of 330 patients. The continuation of the study enables Lundbeck and Otsuka to further explore the efficacy